- Home
- FLYE vs ONCO Comparison
FLYE vs ONCO Comparison
Compare FLYE & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | ONCO |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLYE | ONCO |
|---|---|---|
| Price | $1.52 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 375.2K |
| Earning Date | 04-21-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,063,357.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $0.09 |
| 52 Week High | $21.80 | $6.73 |
Technical Indicators
Market Signals| Indicator | FLYE | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 42.71 |
| Support Level | N/A | $0.61 |
| Resistance Level | $2.39 | $1.01 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 1.49 | 12.54 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. The Company encourages the adoption of eco-friendly transportation for active lifestyles.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.